Michael Schomaker1, Mary-Ann Davies, Karen Malateste, Lorna Renner, Shobna Sawry, Sylvie N'Gbeche, Karl-Günter Technau, François Eboua, Frank Tanser, Haby Sygnaté-Sy, Sam Phiri, Madeleine Amorissani-Folquet, Vivian Cox, Fla Koueta, Cleophas Chimbete, Annette Lawson-Evi, Janet Giddy, Clarisse Amani-Bosse, Robin Wood, Matthias Egger, Valeriane Leroy. 1. From the aCentre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; bInstitute of Epidemiology and Public Health, University of Bordeaux, Bordeaux, France; cUniversity of Ghana Medical School, Accra, Ghana; dWits Reproductive Health and HIV Institute, Harriet Shezi Children's Clinic, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Soweto, South Africa; eCentre de Prise en Charge de Recherche et de Formation Enfants, Abidjan, Côte d'Ivoire; fEmpilweni Service and Research Unit, Rahima Moosa Mother and Child Hospital and University of the Witwatersrand, Johannesburg, South Africa; gYopougon University Hospital, Abidjan, Côte d'Ivoire; hAfrica Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa; iAlbert Royer Hospital, Dakar, Senegal; jLighthouse Trust Clinic, Kamuzu Central Hospital, Lilongwe, Malawi; kUniversity of North Carolina, Chapel Hill, NC; lFélix Houphouët Boigny University Hospital, Abidjan, Côte d'Ivoire; mMédecins Sans Frontiéres South Africa, CapeTown, South Africa; nKhayelitsha ART Programme, Khayelitsha, Cape Town, South Africa; oCharles de Gaulle University Hospital, Ouagadougou, Burkina Faso; pNewlands Clinic, Harare, Zimbabwe; qHospital du Tokoin, Lomé, Togo; rSinikithemba Clinic, McCord Hospital, Durban, South Africa; sMTCT-Plus Center, Abidjan, Côte d'Ivoire; tDesmond Tutu HIV Centre, Cape Town, South Africa; uInstitute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; vInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; and wInserm, U897, Epidémiologie-Biostatistiques, Université Bordeaux, Bordeaux, France.
Abstract
BACKGROUND: There is limited evidence regarding the optimal timing of initiating antiretroviral therapy (ART) in children. We conducted a causal modeling analysis in children ages 1-5 years from the International Epidemiologic Databases to Evaluate AIDS West/Southern-Africa collaboration to determine growth and mortality differences related to different CD4-based treatment initiation criteria, age groups, and regions. METHODS: ART-naïve children of ages 12-59 months at enrollment with at least one visit before ART initiation and one follow-up visit were included. We estimated 3-year growth and cumulative mortality from the start of follow-up for different CD4 criteria using g-computation. RESULTS: About one quarter of the 5,826 included children was from West Africa (24.6%).The median (first; third quartile) CD4% at the first visit was 16% (11%; 23%), the median weight-for-age z-scores and height-for-age z-scores were -1.5 (-2.7; -0.6) and -2.5 (-3.5; -1.5), respectively. Estimated cumulative mortality was higher overall, and growth was slower, when initiating ART at lower CD4 thresholds. After 3 years of follow-up, the estimated mortality difference between starting ART routinely irrespective of CD4 count and starting ART if either CD4 count <750 cells/mm³ or CD4% <25% was 0.2% (95% CI = -0.2%; 0.3%), and the difference in the mean height-for-age z-scores of those who survived was -0.02 (95% CI = -0.04; 0.01). Younger children ages 1-2 and children in West Africa had worse outcomes. CONCLUSIONS: Our results demonstrate that earlier treatment initiation yields overall better growth and mortality outcomes, although we could not show any differences in outcomes between immediate ART and delaying until CD4 count/% falls below 750/25%.
BACKGROUND: There is limited evidence regarding the optimal timing of initiating antiretroviral therapy (ART) in children. We conducted a causal modeling analysis in children ages 1-5 years from the International Epidemiologic Databases to Evaluate AIDS West/Southern-Africa collaboration to determine growth and mortality differences related to different CD4-based treatment initiation criteria, age groups, and regions. METHODS:ART-naïve children of ages 12-59 months at enrollment with at least one visit before ART initiation and one follow-up visit were included. We estimated 3-year growth and cumulative mortality from the start of follow-up for different CD4 criteria using g-computation. RESULTS: About one quarter of the 5,826 included children was from West Africa (24.6%).The median (first; third quartile) CD4% at the first visit was 16% (11%; 23%), the median weight-for-age z-scores and height-for-age z-scores were -1.5 (-2.7; -0.6) and -2.5 (-3.5; -1.5), respectively. Estimated cumulative mortality was higher overall, and growth was slower, when initiating ART at lower CD4 thresholds. After 3 years of follow-up, the estimated mortality difference between starting ART routinely irrespective of CD4 count and starting ART if either CD4 count <750 cells/mm³ or CD4% <25% was 0.2% (95% CI = -0.2%; 0.3%), and the difference in the mean height-for-age z-scores of those who survived was -0.02 (95% CI = -0.04; 0.01). Younger children ages 1-2 and children in West Africa had worse outcomes. CONCLUSIONS: Our results demonstrate that earlier treatment initiation yields overall better growth and mortality outcomes, although we could not show any differences in outcomes between immediate ART and delaying until CD4 count/% falls below 750/25%.
Authors: L D Bwirire; M Fitzgerald; R Zachariah; V Chikafa; M Massaquoi; M Moens; K Kamoto; E J Schouten Journal: Trans R Soc Trop Med Hyg Date: 2008-05-16 Impact factor: 2.184
Authors: Avy Violari; Jane C Lindsey; Michael D Hughes; Hilda A Mujuru; Linda Barlow-Mosha; Portia Kamthunzi; Benjamin H Chi; Mark F Cotton; Harry Moultrie; Sandhya Khadse; Werner Schimana; Raziya Bobat; Lynette Purdue; Susan H Eshleman; Elaine J Abrams; Linda Millar; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Paul Palumbo Journal: N Engl J Med Date: 2012-06-21 Impact factor: 91.245
Authors: Daniel Westreich; Stephen R Cole; Jessica G Young; Frank Palella; Phyllis C Tien; Lawrence Kingsley; Stephen J Gange; Miguel A Hernán Journal: Stat Med Date: 2012-04-11 Impact factor: 2.373
Authors: Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Agnes N Kiragga; Barbara Castelnuovo; Rachel Musomba; Jonathan Levin; Andrew Kambugu; Yukari C Manabe; Constantin T Yiannoutsos; Noah Kiwanuka Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Jessica L Schue; Janneke H van Dijk; Francis Hamangaba; Mutinta Hamahuwa; Nkumbula Moyo; Philip E Thuma; William J Moss; Catherine G Sutcliffe Journal: BMC Pediatr Date: 2021-07-14 Impact factor: 2.125